Cargando…
Female Sex but Not Oestrogen Receptor Expression Predicts Survival in Advanced Gastroesophageal Adenocarcinoma—A Post-hoc Analysis of the GO2 Trial
SIMPLE SUMMARY: Gastroesophageal adenocarcinoma (GOA) is a cancer that has poor survival. Most cases are diagnosed when a cure is not possible, and treatment often has many side effects. It occurs less often and is associated with better outcomes in females. The reason for this is not known. We soug...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10177024/ https://www.ncbi.nlm.nih.gov/pubmed/37174057 http://dx.doi.org/10.3390/cancers15092591 |
_version_ | 1785040540108062720 |
---|---|
author | Baxter, Mark A. Spender, Lindsay C. Walsh, Shaun Bray, Susan Skinner, Gemma King, Sharon Hall, Peter S. Seymour, Matthew J. Petty, Russell D. |
author_facet | Baxter, Mark A. Spender, Lindsay C. Walsh, Shaun Bray, Susan Skinner, Gemma King, Sharon Hall, Peter S. Seymour, Matthew J. Petty, Russell D. |
author_sort | Baxter, Mark A. |
collection | PubMed |
description | SIMPLE SUMMARY: Gastroesophageal adenocarcinoma (GOA) is a cancer that has poor survival. Most cases are diagnosed when a cure is not possible, and treatment often has many side effects. It occurs less often and is associated with better outcomes in females. The reason for this is not known. We sought to use samples from a clinical trial in older adults with GOA to investigate whether this observation could be related to oestrogen and its action through oestrogen receptors. We found no clear link between outcome and oestrogen receptor expression but did note improved survival with older age and female sex. ABSTRACT: Gastroesophageal adenocarcinoma is a disease of older adults that is associated with a very poor prognosis. It is less common and has better outcomes in females. The reason for this is unknown but may relate to signalling via the main oestrogen receptors (ER) α and β. In this study, we sought to investigate this using the GO2 clinical trial patient cohort. GO2 recruited older and/or frail patients with advanced gastroesophageal cancer. Immunohistochemistry was performed on tumour samples from 194 patients. The median age of the population was 76 years (range 52–90), and 25.3% were female. Only one (0.5%) tumour sample was positive for ERα, compared to 70.6% for ERβ expression. There was no survival impact according to ERβ expression level. Female sex and younger age were associated with lower ERβ expression. Female sex was also associated with improved overall survival. To our knowledge, this is the largest study worldwide of ER expression in a cohort of patients with advanced gastroesophageal adenocarcinoma. It is also unique, given the age of the population. We have demonstrated that female sex is associated with better survival outcomes with palliative chemotherapy but that this does not appear to be related to ER IHC expression. The differing ER expression according to age supports the concept of a different disease biology with age. |
format | Online Article Text |
id | pubmed-10177024 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-101770242023-05-13 Female Sex but Not Oestrogen Receptor Expression Predicts Survival in Advanced Gastroesophageal Adenocarcinoma—A Post-hoc Analysis of the GO2 Trial Baxter, Mark A. Spender, Lindsay C. Walsh, Shaun Bray, Susan Skinner, Gemma King, Sharon Hall, Peter S. Seymour, Matthew J. Petty, Russell D. Cancers (Basel) Article SIMPLE SUMMARY: Gastroesophageal adenocarcinoma (GOA) is a cancer that has poor survival. Most cases are diagnosed when a cure is not possible, and treatment often has many side effects. It occurs less often and is associated with better outcomes in females. The reason for this is not known. We sought to use samples from a clinical trial in older adults with GOA to investigate whether this observation could be related to oestrogen and its action through oestrogen receptors. We found no clear link between outcome and oestrogen receptor expression but did note improved survival with older age and female sex. ABSTRACT: Gastroesophageal adenocarcinoma is a disease of older adults that is associated with a very poor prognosis. It is less common and has better outcomes in females. The reason for this is unknown but may relate to signalling via the main oestrogen receptors (ER) α and β. In this study, we sought to investigate this using the GO2 clinical trial patient cohort. GO2 recruited older and/or frail patients with advanced gastroesophageal cancer. Immunohistochemistry was performed on tumour samples from 194 patients. The median age of the population was 76 years (range 52–90), and 25.3% were female. Only one (0.5%) tumour sample was positive for ERα, compared to 70.6% for ERβ expression. There was no survival impact according to ERβ expression level. Female sex and younger age were associated with lower ERβ expression. Female sex was also associated with improved overall survival. To our knowledge, this is the largest study worldwide of ER expression in a cohort of patients with advanced gastroesophageal adenocarcinoma. It is also unique, given the age of the population. We have demonstrated that female sex is associated with better survival outcomes with palliative chemotherapy but that this does not appear to be related to ER IHC expression. The differing ER expression according to age supports the concept of a different disease biology with age. MDPI 2023-05-03 /pmc/articles/PMC10177024/ /pubmed/37174057 http://dx.doi.org/10.3390/cancers15092591 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Baxter, Mark A. Spender, Lindsay C. Walsh, Shaun Bray, Susan Skinner, Gemma King, Sharon Hall, Peter S. Seymour, Matthew J. Petty, Russell D. Female Sex but Not Oestrogen Receptor Expression Predicts Survival in Advanced Gastroesophageal Adenocarcinoma—A Post-hoc Analysis of the GO2 Trial |
title | Female Sex but Not Oestrogen Receptor Expression Predicts Survival in Advanced Gastroesophageal Adenocarcinoma—A Post-hoc Analysis of the GO2 Trial |
title_full | Female Sex but Not Oestrogen Receptor Expression Predicts Survival in Advanced Gastroesophageal Adenocarcinoma—A Post-hoc Analysis of the GO2 Trial |
title_fullStr | Female Sex but Not Oestrogen Receptor Expression Predicts Survival in Advanced Gastroesophageal Adenocarcinoma—A Post-hoc Analysis of the GO2 Trial |
title_full_unstemmed | Female Sex but Not Oestrogen Receptor Expression Predicts Survival in Advanced Gastroesophageal Adenocarcinoma—A Post-hoc Analysis of the GO2 Trial |
title_short | Female Sex but Not Oestrogen Receptor Expression Predicts Survival in Advanced Gastroesophageal Adenocarcinoma—A Post-hoc Analysis of the GO2 Trial |
title_sort | female sex but not oestrogen receptor expression predicts survival in advanced gastroesophageal adenocarcinoma—a post-hoc analysis of the go2 trial |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10177024/ https://www.ncbi.nlm.nih.gov/pubmed/37174057 http://dx.doi.org/10.3390/cancers15092591 |
work_keys_str_mv | AT baxtermarka femalesexbutnotoestrogenreceptorexpressionpredictssurvivalinadvancedgastroesophagealadenocarcinomaaposthocanalysisofthego2trial AT spenderlindsayc femalesexbutnotoestrogenreceptorexpressionpredictssurvivalinadvancedgastroesophagealadenocarcinomaaposthocanalysisofthego2trial AT walshshaun femalesexbutnotoestrogenreceptorexpressionpredictssurvivalinadvancedgastroesophagealadenocarcinomaaposthocanalysisofthego2trial AT braysusan femalesexbutnotoestrogenreceptorexpressionpredictssurvivalinadvancedgastroesophagealadenocarcinomaaposthocanalysisofthego2trial AT skinnergemma femalesexbutnotoestrogenreceptorexpressionpredictssurvivalinadvancedgastroesophagealadenocarcinomaaposthocanalysisofthego2trial AT kingsharon femalesexbutnotoestrogenreceptorexpressionpredictssurvivalinadvancedgastroesophagealadenocarcinomaaposthocanalysisofthego2trial AT hallpeters femalesexbutnotoestrogenreceptorexpressionpredictssurvivalinadvancedgastroesophagealadenocarcinomaaposthocanalysisofthego2trial AT seymourmatthewj femalesexbutnotoestrogenreceptorexpressionpredictssurvivalinadvancedgastroesophagealadenocarcinomaaposthocanalysisofthego2trial AT pettyrusselld femalesexbutnotoestrogenreceptorexpressionpredictssurvivalinadvancedgastroesophagealadenocarcinomaaposthocanalysisofthego2trial AT femalesexbutnotoestrogenreceptorexpressionpredictssurvivalinadvancedgastroesophagealadenocarcinomaaposthocanalysisofthego2trial |